Brief: Imara Announces Results Of Interim Analyses Of Tovinontrine Phase 2B Clinical Trials In Sickle Cell Disease And Beta-Thalassemia

Enliven Therapeutics

05/04/2022 12:03

April 5 (Reuters) - Imara Inc  IMRA.O :
    * IMARA ANNOUNCES RESULTS OF INTERIM ANALYSES OF
TOVINONTRINE
(IMR-687) PHASE 2B CLINICAL TRIALS IN SICKLE CELL DISEASE AND
BETA-THALASSEMIA
    * IMARA - INTERIM RESULTS IN ARDENT TRIAL FOR SICKLE CELL
DISEASE
SHOWED NO SIGNIFICANT DIFFERENCE IN MEDIAN ANNUALIZED RATE OF
VASO-OCCLUSIVE CRISES
    * IMARA INC - TOVINONTRINE WAS GENERALLY WELL-TOLERATED
ACROSS
STUDIES
    * IMARA - INTERIM RESULTS IN FORTE TRIAL FOR
BETA-THALASSEMIA
DEMONSTRATED NO MEANINGFUL BENEFIT IN TRANSFUSION
BURDEN/IMPROVEMENT IN MOST DISEASE-RELATED BIOMARKERS
    * IMARA INC - BOTH PHASE 2B CLINICAL TRIALS AND FURTHER
DEVELOPMENT OF TOVINONTRINE IN SICKLE CELL AND BETA-THALASSEMIA
TO BE DISCONTINUED

Source text for Eikon:  ID:nGNX52cJvw 
Further company coverage:  IMRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))